chr16-13920181-C-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_005236.3(ERCC4):c.16C>T(p.Pro6Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000612 in 1,605,836 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_005236.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ERCC4 | NM_005236.3 | c.16C>T | p.Pro6Ser | missense_variant | 1/11 | ENST00000311895.8 | NP_005227.1 | |
ERCC4 | XM_011522424.4 | c.16C>T | p.Pro6Ser | missense_variant | 1/12 | XP_011520726.1 | ||
LOC105371093 | XR_007064999.1 | n.82+6344G>A | intron_variant | |||||
LOC105371093 | XR_007065000.1 | n.82+6344G>A | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ERCC4 | ENST00000311895.8 | c.16C>T | p.Pro6Ser | missense_variant | 1/11 | 1 | NM_005236.3 | ENSP00000310520.7 |
Frequencies
GnomAD3 genomes AF: 0.000532 AC: 81AN: 152254Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000458 AC: 111AN: 242132Hom.: 0 AF XY: 0.000423 AC XY: 56AN XY: 132282
GnomAD4 exome AF: 0.000621 AC: 902AN: 1453464Hom.: 0 Cov.: 35 AF XY: 0.000607 AC XY: 439AN XY: 723482
GnomAD4 genome AF: 0.000532 AC: 81AN: 152372Hom.: 0 Cov.: 33 AF XY: 0.000550 AC XY: 41AN XY: 74518
ClinVar
Submissions by phenotype
not provided Uncertain:5
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 04, 2022 | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in individuals with breast, ovarian, or lung cancer (Matakidou 2006, Maxwell 2016); This variant is associated with the following publications: (PMID: 24728327, 16550608, 27153395) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden | Nov 03, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 02, 2018 | - - |
Uncertain significance, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
not specified Uncertain:2Other:1
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 07, 2023 | Variant summary: ERCC4 c.16C>T (p.Pro6Ser) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00046 in 242132 control chromosomes. The observed variant frequency is approximately 2.37 fold of the estimated maximal expected allele frequency for a pathogenic variant in ERCC4 causing Xeroderma Pigmentosum phenotype (0.00019), suggesting that the variant may be benign. However no homozygous control individuals were observed. c.16C>T has been reported in the literature in at least one heterozygous individual affected with familial early-onset skin cancer without evidence of cosegregation (e.g. Matakidou_2006). These report(s) do not provide unequivocal conclusions about association of the variant with Xeroderma Pigmentosum. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Twelve submitters have cited clinical-significance assessments for this variant to ClinVar after 2014, all classifying the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Uncertain significance, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 18, 2022 | DNA sequence analysis of the ERCC4 gene demonstrated a sequence change, c.16C>T, in exon 1 that results in an amino acid change, p.Pro6Ser. This sequence change has been previously described in individuals with lung cancer (PMID: 16550608) and breast and/or ovarian cancer (PMID: 27153395). This sequence change has been described in the gnomAD database with a frequency of 0.09% in the European subpopulation (dbSNP rs61760160). The p.Pro6Ser change affects a poorly conserved amino acid residue located in a domain of the ERCC4 protein that is known to be functional. The p.Pro6Ser substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Pro6Ser change remains unknown at this time. - |
Fanconi anemia complementation group Q Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | St. Jude Molecular Pathology, St. Jude Children's Research Hospital | Sep 22, 2022 | The ERCC4 c.16C>T (p.Pro6Ser) missense change has a maximum subpopulation frequency of 0.093% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL is inconclusive about a pathogenic or benign effect of this variant on protein function, and to our knowledge functional studies have not been performed. This variant has been reported in individuals with a personal and/or family history of lung cancer (PMID: 16550608) and breast cancer (PMID: 27153395). To our knowledge, this variant has not been reported in individuals with Fanconi anemia or Xeroderma pigmentosum. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 13, 2020 | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Xeroderma pigmentosum, group F Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
Cockayne syndrome;C0268140:Xeroderma pigmentosum, group F;C3808988:Fanconi anemia complementation group Q Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 6 of the ERCC4 protein (p.Pro6Ser). This variant is present in population databases (rs61760160, gnomAD 0.09%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with lung cancer (PMID: 16550608). ClinVar contains an entry for this variant (Variation ID: 134131). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The serine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Xeroderma pigmentosum Uncertain:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Sep 15, 2021 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 04, 2022 | The c.16C>T (p.P6S) alteration is located in exon 1 (coding exon 1) of the ERCC4 gene. This alteration results from a C to T substitution at nucleotide position 16, causing the proline (P) at amino acid position 6 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Xeroderma pigmentosum, group F;C1970416:XFE progeroid syndrome;C3808988:Fanconi anemia complementation group Q Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 29, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at